News Releases

Date Title and Summary
Toggle Summary electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York
ROCKAWAY, N.J. , March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief Medical Officer, Dr. Peter Staats , will keynote the Fifth Annual Bioelectronic Medicine Forum on April
Toggle Summary electroCore to Present at 2022 Maxim Virtual Growth Conference
ROCKAWAY, N.J. , March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger , will be presenting at the 2022 Maxim Virtual Growth Conference .
Toggle Summary electroCore Announces Fourth Quarter and Full Year 2021 Financial Results
Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020 Ended 2021 with cash and cash equivalents of $34.7 million Company to host conference call and webcast today, March 10, 2022 , at 4:30 PM EST ROCKAWAY, N.J.
Toggle Summary electroCore Announces Changes to its Board of Directors
Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience ROCKAWAY, N.J. , March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of
Toggle Summary electroCore to Present at 34th Annual Roth Conference
ROCKAWAY, N.J. , March 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be presenting at the 34th Annual Roth Conference . Details for access to the presentation are as
Toggle Summary electroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results on Thursday, March 10
Conference Call to be Held at 4:30 PM Eastern Standard Time ROCKAWAY, N.J. , March 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the fourth quarter and year ended December
Toggle Summary Data Presented at 2022 International Stroke Congress Suggests Role for Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Stroke
Clinical Trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative Ischemic Lesion Growth Decreased by 65.9% with nVNS vs. Sham Treatment. ROCKAWAY, N.J. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic
Toggle Summary electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus
Data on 97-patient, randomized, sham-controlled study to be presented at medical congress later this year ROCKAWAY, N.J. , Feb. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced enrollment has been completed for the
Toggle Summary electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022
Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Stroke ROCKAWAY, N.J. , Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the
Toggle Summary electroCore Announces Shareholder Letter and Full-Year 2021 Business Update
Company anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% increase over full-year 2020 ROCKAWAY, N.J. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) today published a letter from the company’s Board of Directors to shareholders.